Tabula
8 known investors
Find your way into Tabula
Tabula Bio uses machine learning to design in-context DNA algorithms that can outpace microbial evolution and treat infectious disease, positioning itself as an alternative to traditional antibiotic and drug development. The company applies AI to design new DNA faster than pathogens can evolve resistance, and states it is already treating patients.
Investors · 8
Maven Ventures✓ verifiedPalo Alto · $1M
Zypsy CapitalSan Francisco · $50K – $400K
Balderton CapitalreportedLondon · $5M – $50M
BenchmarkreportedSan Francisco · $100K – $30M
Crosslink CapitalreportedSan Francisco · $1M – $9M
Dag VenturesreportedPalo Alto
Greylock PartnersreportedSan Francisco · $100K – $200M
New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40M
In the news
Frequently asked questions
- What does Tabula do?
- Tabula Bio uses machine learning to design in-context DNA algorithms that can outpace microbial evolution and treat infectious disease, positioning itself as an alternative to traditional antibiotic and drug development. The company applies AI to design new DNA faster than pathogens can evolve resistance, and states it is already treating patients.
- Who are Tabula's investors?
- Tabula's investors include Maven Ventures, Zypsy Capital, Balderton Capital, Benchmark, Crosslink Capital, Dag Ventures, Greylock Partners, New Enterprise Associates (NEA).






